Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypertension, Grade 1 Clear all
Terminated Phase 2 Interventional

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

NCT01373086
View directory record Official record
Conditions
Hypertension
Interventions
LFF269, Eplerenone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
11
States / cities
Anaheim, California • Fort Myers, Florida • Miramar, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 2Phase 3 Interventional

AVE7688 in Patients With Mild to Moderate Blood Pressure

NCT00284128
View directory record Official record
Conditions
Hypertension
Interventions
AVE7688, Losartan-potassium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 4 Interventional

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

NCT00239538
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

NCT00200473
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2005 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 2 Interventional

A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

NCT02083289
View directory record Official record
Conditions
Ocular Hypertension, Open Angle-glaucoma
Interventions
ONO-9054, Latanoprost
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
12
States / cities
Los Angeles, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 4 Interventional

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

NCT00034840
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan, valsartan
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.

NCT00250562
View directory record Official record
Conditions
Hypertension
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 3 Interventional

Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension

NCT00145236
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

NCT00200421
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Jul 22, 2026, 11:49 PM EDT
Recruiting Not applicable Interventional

Effect of Electro-Acupuncture on Blood Pressure

NCT00932139
View directory record Official record
Conditions
Hypertension
Interventions
Electro-acupuncture control, Electro-acupuncture test
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Not applicable Interventional

Mild Preeclampsia Near Term: Deliver or Deliberate?

NCT00789919
View directory record Official record
Conditions
Preeclampsia
Interventions
Delivery of infant
Procedure
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Idiopathic Intracranial Hypertension Treatment Trial

NCT01003639
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Placebo, Formal weight loss counselling program
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry

NCT03804684
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL Field Analyzer
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Jul 22, 2026, 11:49 PM EDT
Terminated Not applicable Interventional

Safety and Effectiveness of the Hydrus Microstent

NCT05198297
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 22, 2026, 11:49 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma

NCT05583591
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
Device
Lead sponsor
Diablo Eye Associates
Industry
Eligibility
60 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects

NCT01974570
View directory record Official record
Conditions
Prehypertension
Interventions
Marealis refined peptide concentrate, Placebo
Dietary Supplement
Lead sponsor
KGK Science Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

NCT04200573
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions
Ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 3 Interventional

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

NCT00200434
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2005 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Results available

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

NCT00422461
View directory record Official record
Conditions
Hypertension
Interventions
placebo, PF-00489791
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Los Angeles, California • Santa Ana, California • Tustin, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 22, 2026, 11:49 PM EDT
Recruiting Phase 4 Interventional

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

NCT07247058
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Interventions
Osilodrostat (Isturisa)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 11:49 PM EDT
Recruiting Not applicable Interventional

Acupuncture Therapy and Hypertension

NCT05530512
View directory record Official record
Conditions
Mild to Moderate Hypertension
Interventions
electroacupuncture
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
45 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Not applicable Interventional

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

NCT01258764
View directory record Official record
Conditions
Hypertension, Grade 1, Hypertension Treatment, N of 1 Study Design, Hypertension
Interventions
Lisinopril, Hydrochlorothiazide
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Macronutrient Effects on Alzheimer's Disease (MEAL-2)

NCT02463084
View directory record Official record
Conditions
Prediabetic State, Insulin Resistance, Middle Age, Prehypertension, Mild Cognitive Impairment
Interventions
Low Diet, High Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Jul 22, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

NCT03714776
View directory record Official record
Conditions
Mild Hypertension
Interventions
Placebo, ISIS 757456
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
6
States / cities
Tustin, California • Port Orange, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jul 22, 2026, 11:49 PM EDT